检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:国长军[1] 于同虎[1] 张华平[1] 邢建华[1]
机构地区:[1]烟台毓璜顶医院胃肠外二科,山东烟台264000
出 处:《中国医药导报》2011年第28期54-55,共2页China Medical Herald
摘 要:目的:观察华蟾素注射液联合化疗对晚期胃癌的治疗效果。方法:86例晚期胃癌患者随机分为两组。观察组43例,采用多西他塞注射液(多帕菲)120 mg+0.9%氯化钠250 ml静脉滴注d1,3周重复,同时加用华蟾素注射液20 ml+0.9%氯化钠250 ml,1次/d,静脉滴注,连用2周休息1周为1个周期。对照组43例,采用多西他塞注射液120 mg+0.9%氯化钠250 ml静脉滴注d1,3周重复。两组均用3个周期。结果:两组近期疗效及不良反应差异无统计学意义(P>0.05),观察组疼痛缓解率为79.07%,提高生活质量的有效率76.74%;对照组疼痛缓解率32.56%,提高生活质量的有效率为55.81%,两组比较差异均有统计学意义(P<0.05)。结论:华蟾素注射液联合多西他塞注射液治疗晚期胃癌能明显缓解疼痛,改善生活质量,是一种安全有效的姑息治疗方法。Objective: To investigate the clinical therapeutic effect of Cinobufacini combined with Docetaxel on the advanced stomach cancer.Methods: 86 patients with advanced stomach cancer were randomly divided into observation group(43 cases) and control group(43 cases).The patients in the observation group were treated continuously with Docetaxel 120 mg +0.9% sodium chloride 250 ml d1 for 3 weeks as onecycle,meanwhile continuously with Cinobufacini 20 ml + 0.9% sodium chloride 250 ml intravenous drip for 2 weeks,once a day,2 weeks treatment and 1 week rest for 1 cycle;while the patients in the control group were treated continuously with Docetaxel 120 mg+0.9% sodium chloride 250 ml d1 only for 3 weeks as one cycle.two groups were all treated with three circles.Results: There was no statistical difference in curative effect and adverse reaction between the two groups(P〉0.05).However there were significant differences between the two groups in the pain relief rate(79.09% vs 32.56%) and the effective rate of increasing life quality(76.74% vs 55.81%).Conclusion: Cinobufacini combined with Docetaxel can alleviate pain distinctly and improve the life quality for the patients with advanced stomach cancer.It is a safe and effective appeasement therapeutic method.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.249